Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKTX NASDAQ:BCLI NASDAQ:CVKD NASDAQ:DARE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKTXAkari Therapeutics$0.93-8.8%$0.91$0.57▼$3.15$30.33M0.36461,988 shs156,335 shsBCLIBrainstorm Cell Therapeutics$0.69-3.5%$0.69$0.52▼$2.68$7.67M0.3508,436 shs19,360 shsCVKDCadrenal Therapeutics$13.62-4.0%$12.92$8.74▼$22.90$27.88M0.9629,709 shs21,454 shsDAREDare Bioscience$2.12-4.9%$2.11$1.83▼$9.19$28.58M1.14130,941 shs159,462 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKTXAkari Therapeutics0.00%+1.53%+20.78%-17.75%-68.47%BCLIBrainstorm Cell Therapeutics0.00%-3.46%-2.20%-42.09%-66.27%CVKDCadrenal Therapeutics0.00%-3.95%+0.89%+5.42%+13.97%DAREDare Bioscience0.00%-2.75%+0.47%-15.87%-34.97%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKTXAkari Therapeutics$0.93-8.8%$0.91$0.57▼$3.15$30.33M0.36461,988 shs156,335 shsBCLIBrainstorm Cell Therapeutics$0.69-3.5%$0.69$0.52▼$2.68$7.67M0.3508,436 shs19,360 shsCVKDCadrenal Therapeutics$13.62-4.0%$12.92$8.74▼$22.90$27.88M0.9629,709 shs21,454 shsDAREDare Bioscience$2.12-4.9%$2.11$1.83▼$9.19$28.58M1.14130,941 shs159,462 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKTXAkari Therapeutics0.00%+1.53%+20.78%-17.75%-68.47%BCLIBrainstorm Cell Therapeutics0.00%-3.46%-2.20%-42.09%-66.27%CVKDCadrenal Therapeutics0.00%-3.95%+0.89%+5.42%+13.97%DAREDare Bioscience0.00%-2.75%+0.47%-15.87%-34.97%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKTXAkari Therapeutics 2.33Hold$3.30254.84% UpsideBCLIBrainstorm Cell Therapeutics 2.00HoldN/AN/ACVKDCadrenal Therapeutics 2.00Hold$32.00134.95% UpsideDAREDare Bioscience 2.33Hold$10.00371.70% UpsideCurrent Analyst Ratings BreakdownLatest BCLI, AKTX, DARE, and CVKD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025AKTXAkari TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025CVKDCadrenal TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025DAREDare BioscienceWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025AKTXAkari TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025CVKDCadrenal TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025DAREDare BioscienceWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/9/2025AKTXAkari TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$1.609/4/2025DAREDare BioscienceMaxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Buy$8.007/23/2025BCLIBrainstorm Cell TherapeuticsMaxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold7/18/2025AKTXAkari TherapeuticsMaxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$5.00(Data available from 10/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKTXAkari TherapeuticsN/AN/AN/AN/A$0.84 per shareN/ABCLIBrainstorm Cell TherapeuticsN/AN/AN/AN/A($1.36) per shareN/ACVKDCadrenal TherapeuticsN/AN/AN/AN/A$4.17 per shareN/ADAREDare Bioscience$10K2,857.76N/AN/A($0.69) per share-3.07Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKTXAkari Therapeutics-$19.79MN/A0.00∞N/AN/A-78.03%-31.62%11/18/2025 (Estimated)BCLIBrainstorm Cell Therapeutics-$11.62M-$3.10N/AN/AN/AN/AN/A-519.50%11/13/2025 (Estimated)CVKDCadrenal Therapeutics-$10.65M-$8.88N/AN/AN/AN/A-265.37%-196.38%11/6/2025 (Estimated)DAREDare Bioscience-$4.05M-$2.14N/AN/AN/AN/AN/A-103.70%11/13/2025 (Estimated)Latest BCLI, AKTX, DARE, and CVKD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/6/2025Q3 2025CVKDCadrenal Therapeutics-$1.55N/AN/AN/AN/AN/A8/14/2025Q2 2025DAREDare Bioscience-$0.55-$0.45+$0.10-$0.45$0.14 million($0.02) million8/11/2025Q2 2025CVKDCadrenal Therapeutics-$1.60-$1.87-$0.27-$1.87N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKTXAkari TherapeuticsN/AN/AN/AN/AN/ABCLIBrainstorm Cell TherapeuticsN/AN/AN/AN/AN/ACVKDCadrenal TherapeuticsN/AN/AN/AN/AN/ADAREDare BioscienceN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKTXAkari TherapeuticsN/A0.190.19BCLIBrainstorm Cell TherapeuticsN/A0.210.21CVKDCadrenal TherapeuticsN/A3.553.55DAREDare BioscienceN/A0.340.34Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKTXAkari Therapeutics5.06%BCLIBrainstorm Cell Therapeutics14.33%CVKDCadrenal Therapeutics7.92%DAREDare Bioscience6.70%Insider OwnershipCompanyInsider OwnershipAKTXAkari Therapeutics38.10%BCLIBrainstorm Cell Therapeutics11.15%CVKDCadrenal Therapeutics26.09%DAREDare Bioscience4.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKTXAkari Therapeutics932.62 million20.19 millionNot OptionableBCLIBrainstorm Cell Therapeutics4011.04 million8.74 millionOptionableCVKDCadrenal Therapeutics42.05 million1.51 millionNot OptionableDAREDare Bioscience3013.48 million12.83 millionNot OptionableBCLI, AKTX, DARE, and CVKD HeadlinesRecent News About These CompaniesDare Bioscience receives $4M non-dilutive grant installmentOctober 6, 2025 | msn.comDare Bioscience Receives $4 Million Non-Dilutive Grant Installment; Total of $41.8M Received to Date of up to $49M Commitment Supporting Smart Drug Delivery Device for ...October 6, 2025 | markets.businessinsider.comDaré Bioscience, Inc.: Daré Bioscience to Receive up to $499,000 to Support Preeclampsia ResearchSeptember 24, 2025 | finanznachrichten.deDaré Bioscience to Receive up to $499,000 to Support Preeclampsia ResearchSeptember 24, 2025 | globenewswire.comMaxim Group Upgrades Daré Bioscience (DARE)September 6, 2025 | msn.comDare Bioscience upgraded to Buy from Hold at MaximSeptember 4, 2025 | msn.comDaré Bioscience Engages Market with New PresentationSeptember 3, 2025 | msn.comDaré Bioscience, Inc. (NASDAQ:DARE) Q2 2025 Earnings Call TranscriptAugust 16, 2025 | msn.comDaré Bioscience Announces Q2 2025 Financial ResultsAugust 15, 2025 | msn.comDaré Bioscience, Inc.: Daré Bioscience Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateAugust 15, 2025 | finanznachrichten.deDaré Bioscience targets Q4 2025 launch for DARE to PLAY Sildenafil cream while advancing dual-path strategyAugust 14, 2025 | msn.comDaré Bioscience, Inc. (DARE) Q2 2025 Earnings Call TranscriptAugust 14, 2025 | seekingalpha.comDare Bioscience, Inc. (DARE) Reports Q2 Loss, Lags Revenue EstimatesAugust 14, 2025 | zacks.comDaré Bioscience Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateAugust 14, 2025 | globenewswire.comA Preview Of Dare Bioscience's EarningsAugust 13, 2025 | benzinga.comDaré Bioscience to Host Second Quarter 2025 Financial Results and Company Update Conference Call and Webcast on August 14, 2025August 7, 2025 | globenewswire.comDaré starts push to arouse interest in women’s sexual health drug, tapping app for education driveJuly 30, 2025 | fiercepharma.comFDaré Bioscience and Rosy Wellness Launch First Phase of Patient-Focused Campaign to Support ...July 29, 2025 | bakersfield.comBDaré Bioscience, Inc.: Daré Bioscience and Rosy Wellness Launch First Phase of Patient-Focused Campaign to Support DARE to PLAY Sildenafil CreamJuly 29, 2025 | finanznachrichten.deDaré Bioscience and Rosy Wellness Launch First Phase of Patient-Focused Campaign to Support DARE to PLAY™ Sildenafil CreamJuly 29, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBCLI, AKTX, DARE, and CVKD Company DescriptionsAkari Therapeutics NASDAQ:AKTX$0.93 -0.09 (-8.82%) Closing price 10/10/2025 04:00 PM EasternExtended Trading$0.92 -0.01 (-0.54%) As of 10/10/2025 07:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.Brainstorm Cell Therapeutics NASDAQ:BCLI$0.69 -0.03 (-3.49%) As of 10/10/2025 03:45 PM EasternBrainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.Cadrenal Therapeutics NASDAQ:CVKD$13.62 -0.57 (-4.02%) Closing price 10/10/2025 03:59 PM EasternExtended Trading$13.89 +0.27 (+1.98%) As of 10/10/2025 06:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.Dare Bioscience NASDAQ:DARE$2.12 -0.11 (-4.93%) Closing price 10/10/2025 04:00 PM EasternExtended Trading$2.12 0.00 (-0.24%) As of 10/10/2025 05:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Daré Bioscience, Inc., a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older. It is developing Ovaprene, a hormone-free, monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia on demand for the treatment of female sexual arousal disorder; DARE-HRT1 to treat moderate to-severe vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of moderate-to-severe dyspareunia or pain during sexual intercourse; and DARE-CIN to treat cervical intraepithelial neoplasia and other human papillomavirus related pathologies. The company is also developing DARE-PDM1 for the treatment of primary dysmenorrhea; DARE-204 and DARE-214, an injectable formulations contraception of etonogestrel designed to provide contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. In addition, it is developing DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; DARE-GML, a multi-target antimicrobial agent; DARE-RH1, a novel approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; and DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein. Daré Bioscience, Inc. is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Broadcom Gets Second $420 Target as CPO Win Boosts Outlook AST SpaceMobile's Big Win: Shares Soar on New Deal With Verizon Microsoft 365 Premium Marks the Next Phase of AI Monetization 3 Reasons to Buy Sprouts Farmers Market Ahead of Earnings Bassett Furniture: Buy Now, Sit Back, and Collect Dividends Why Amazon’s Prime Day May Be the Catalyst for a Year-End Rally PepsiCo’s Deep Discount Will Soon Evaporate: Buy It While You Can Bargain Alert: DraftKings Is the Most Oversold It’s Ever Been Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
